iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results VANCOUVER, Canada- iCo Therapeutics Inc.(TSX-V: ICO) is pleased to provide further preclinical results supporting the accelerated development of iCo-009, the company's oral reformulation of Amphotericin B (Amp B).
Amp B is a...
High-dose amphotericin B speeds clearance of cryptococcus from the brain HIV infection may be a risk factor for single-drug resistance in tuberculosis infection, and its evolution into multi-drug resistance, according to a brief report in the July 1st issue of the Journal of Infectious Diseases.Single-drug...
Corticosteroids for Blastomycosis-Induced ARDS: A Report of Two Patients and Review of the Literature Corticosteroids for Blastomycosis-Induced ARDS* Tim Lahm, MD; Sheila Neese, MD; Aaron T.Thornburg, DO; Michael D.
Ober, MD; George A.
Sarosi, MD, FCCP and Chadi A.
Hage, MD, FCCP * From the Department of Medicine, Division of...
Warning to Gardeners about Deadly Fungus The man's fungal infection was treated with intravenous liposomal amphotericin and extra-corporeal membrane oxygenation but his blood pressure remained too low and he developed acute kidney failure.His health declined despite...
Gardeners: Be Cautious Of These Fungal Spores Patient / Public: Health Professional: Article Opinions: A previously healthy man died after inhaling fungal spores from dead plant material while gardening in May 2007, and is discussed in a Case Report released on June 13, 2008 in The...
Oral Thrush - What's Been Proved to Work Oropharyngeal candidiasis (OPC), or candidiasis of the mouth and throat, is more commonly known as 'thrush'.It's a fungal infection caused by Candida albicans, which is normally found on the skin or mucous membranes.
If there are...
Novel approach to drug insolubility strengthens PolyTherics patent estate Medical Patent News Polytherics Ltd, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy that specialises in the targeted application of polymers to biopharmaceuticals, has announced the grant...
CD4 count and PCR key to predicting relapses of leishmaniasis A group of French investigators have proposed guidelines for secondary prophylaxis of leishmaniasis among people with HIV.They report in the May 1st issue of the Journal of Acquired Immune Deficiency Syndromes that CD4 cell counts and PCR...
Novel Approach to Drug Insolubility Strengthens PolyTherics Patent Estate -Polytherics Ltd (PolyTherics), a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy that specialises in the targeted application of polymers to biopharmaceuticals, today announced the grant of...
iCo Therapeutics Announces $1,140,450 Financing VANCOUVER, June 2 /CNW/ - iCo Therapeutics Inc.(TSX-V: ICO) announced today that it intends to complete a non-brokered private placement to raise gross proceeds of $1,140,450 through the issuance of 3,801,500 common shares at a price of ...
iCo Therapeutics Announces $1,140,450 Financing Financing VANCOUVER, June 2 /CNW/ - iCo Therapeutics Inc.(TSX-V: ICO) announced today that it intends to complete a non-brokered private placement to raise gross proceeds of $1,140,450 through the issuance of 3,801,500 common shares at a...
Polytherics Complex technology to make drug solubility simple 02-Jun-2008 - UK-based biopharmaceutical company Polytherics hopes that its polymer technology can offer drugmakers a new method of solubilising solid dosage medications.The technology, which recently received European patent protection,...
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pn COLLEGEVILLE, Pa., May 29 (HSMN NewsFeed) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that the U.S.Food and Drug Administration (FDA) has issued an approvable letter for the first-in-class antibiotic...
Wyeth Receives Approvable Letter From FDA For TYGACIL For The Treatment Of Patients With Community-Acquired Pn Wyeth Pharmaceuticals, a division of Wyeth, announced recently that the U.S.Food and Drug Administration (FDA) has issued an approvable letter for the first-in-class antibiotic TYGACIL (tigecycline) for the treatment of adult patients...
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pn Important Safety Information -- To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections proven or strongly suspected to be...
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth (News) Pharmaceuticals, a division of Wyeth , announced today that the U.S.Food and Drug Administration (FDA) has issued an approvable letter for the first-in-class antibiotic...
Novel Approach To Drug Insolubility Strengthens PolyTherics Patent Estate Current Article Ratings: Patient / Public: Health Professional: Article Opinions: 0 posts Polytherics Ltd ('PolyTherics'), a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy that specialises...
Aerosolized liposomal amphotericin B prevents pulmonary aspergillosis NEW YORK (Reuters Health) - Prophylactic inhalation of aerosolized liposomal amphotericin B is an effective way to prevent invasive pulmonary aspergillosis (IPA) in high-risk patients with chemotherapy-induced prolonged neutropenia,...
Aerosolized liposomal amphotericin B prevents pulmonary aspergillosis NEW YORK (Reuters Health) - Prophylactic inhalation of aerosolized liposomal amphotericin B is an effective way to prevent invasive pulmonary aspergillosis (IPA) in high-risk patients with chemotherapy-induced prolonged neutropenia,...
Aerosolized liposomal amphotericin B prevents pulmonary aspergillosis By Megan Rauscher NEW YORK (Reuters Health) - Prophylactic inhalation of aerosolized liposomal amphotericin B is an effective way to prevent invasive pulmonary aspergillosis (IPA) in high-risk patients with chemotherapy-induced...
Carbon dioxide enhancement of inhalation therapy Title: United States Patent: RE40,300 Inventors: Waldrep; J.Clifford (The Woodlands, TX), Knight; J.
Vernon (Houston, TX), Koshkina; Nadezhda (Houston, TX) Assignee: Research Development Foundation (Carson City, NV) Appl.
No.: 10/927...
Method of enhancing a targeted immune response against tumors The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or...
iCo Therapeutics acquires worldwide rights to oral Amphotericin B iCo Therapeutics Inc.has acquired the exclusive worldwide rights to iCo-009, an oral reformulation of Amphotericin B ('Amp B') for the treatment of systemic fungal infections and Leishmaniasis.
AmpB is a generic drug that has been...
iCo acquires rights to oral antifungal drug AmpB is a generic drug that has been in use for approximately 50 years and is considered one of the most effective agents in the treatment of systemic fungal infections.Current use of Amp B is limited as it is currently administered...
iCo Therapeutics Year-End 2007 Financial Results /CNW/ - iCo Therapeutics Inc.(TSX-V: ICO) today reported financial results for the year ended December 31, 2007.
Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted...
